Lexaria Bioscience Corp. LEXX Archives - Page 5 of 39

MondayMar 25, 2024 12:45 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires Contract Research Organization to Perform Important GLP-1 Human Pilot Study

Lexaria, a global innovator in drug delivery platforms, recently hired a Contract Research Organization to perform their second GLP-1 human pilot study which will test a dissolvable DehydraTECH-GLP-1 oral dose formulation The announcement follows Lexaria’s WEIGHT-A24-1 animal study announcement examining diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and cannabidiol alone and in combination The move aligns with the company’s resolve to focus on their ability to enhance the delivery of GLP-1 diabetes and obesity drugs At the beginning of the year, Lexaria Bioscience (NASDAQ: LEXX), a global innovator for enhanced drug delivery platforms, announced its intention to double…

ThursdayMar 21, 2024 1:56 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO to Present at the Upcoming 14th Annual LD Micro Invitational

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, has announced that it will be participating at the 14th Annual LD Micro Invitational at the Sofitel New York on Apr. 8-9, 2024. Lexaria CEO Chris Bunka will be presenting at the event, with his presentation scheduled to begin at 10:30 a.m. ET on Tuesday, Apr. 9. Bunka will discuss the company’s recent discovery of enhanced performance of glucagon-like-peptide-1 (“GLP-1”) drugs utilizing DehydraTECH. The presentation will also cover the highly anticipated upcoming animal and clinical studies in humans to more thoroughly evaluate the impact of DehydraTECH processing on…

ThursdayMar 21, 2024 9:00 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Achieves 7% Weight Loss; Sets Stage for 8-week Diabetes and Weight Loss Animal Study

Lexaria, a global innovator in drug delivery platforms, highlighted results from its DIAB-A22-1 animal study, highlighting a 7% reduction in weight and a 19.9% reduction in blood glucose With this success, Lexaria looks to kick off its WEIGHT-A24-1 animal study to examine diabetes and weight loss effects of its patented DehydraTECH(TM)-processed GLP-1 drugs and DehydraTECH-processed CBD The study will comprise 12 arms and involve 72 animals. It will run for a total of 12 weeks This study will build on previous studies that evidenced DehydraTECH’s potential to enable greater penetration of GLP-1 drugs into the brain tissue Lexaria Bioscience (NASDAQ:…

MondayMar 18, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Marks Huge 2024 Milestone with FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria, a global innovator in drug delivery platforms, recently received FDA clearance for its HYPER-H23-1 clinical study John Docherty, President of Lexaria, has regarded this milestone as a demonstration of its patented DehydraTECH(TM) technology’s overall viability, particularly in the potential treatment of hypertension With HYPER-H23-1, Lexaria looks to build on the success of its previous human clinical studies, whose results have been overwhelmingly positive This marks a considerable milestone even as the company looks to double down on GLP-1 studies for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the…

ThursdayMar 14, 2024 3:02 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan, CPA, will serve in the position, which also entails being a member of Lexaria’s executive leadership team. Cabatuan brings more than 15 years of corporate finance and operations experience in the life sciences industry. Most recently, he served as senior vice president of finance and operations at Rain Oncology Inc., a late-stage precision oncology biotech company. In that position, he was pivotal in building and leading the company’s financial organization, resulting in significant growth…

FridayMar 08, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Banking on DehydraTECH(TM) Technology for Major 2024 Growth

Lexaria, a global innovator in drug delivery platforms, has, since 2016, proven its patented DehydraTECH(TM) technology, asserting its superiority in improving drug bioavailability This has earned it 39 granted patents, with many pending globally DehydraTECH has a number of potential pharmaceutical applications with successful early stage results in hypertension, diabetes and weight loss and many others With its focus on GLP-1 clinical studies for 2024, Lexaria looks to carve out greater market share to make 2024 its biggest year Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been pushing the envelope and redefining drug delivery technology.…

ThursdayMar 07, 2024 1:58 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO for Second DehydraTECH-Powered GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to perform the company’s second DehydraTECH-powered glucagon-like peptide 1 (“GLP-1”) human pilot study #2. According to the announcement, the study will be a randomized, crossover, placebo-controlled investigation that will compare three formulations, each at a 7 mg semaglutide dose: a positive control Rybelsus(R) swallowed tablet; DehydraTECH-semaglutide swallowed capsules; and, for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. “DehydraTECH has previously shown an ability to improve delivery of certain drugs destined for the bloodstream, through the…

TuesdayMar 05, 2024 3:21 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Commence Diabetes and Weight Loss Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details for an eight-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol, alone and in combination. The contract for the study was awarded to a third-party, Health Canada-licensed research laboratory. Manufacturing of the compositions for the first eight of the 12 study arms has been completed, and those arms will commence as soon as possible at the testing laboratory, expected to begin within 45 days. Each arm of the study will be dosed for…

MondayMar 04, 2024 12:39 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting glucose reduction and weight-loss results in a testing of its wholly owned and patented DehydraTECH-CBD formulation. According to the announcement, when administered to rodents in an eight-week study, DehydraTech-CBD resulted in weight loss of 7% and a reduction of 19.9% (p<0.05) in blood glucose. As a result, Lexaria has now signed contracts to begin a large, multiweek animal study that will substantially progress its DehydraTECH-GLP-1 and DehydraTECH-CBD weight-loss investigations. In addition, the announcement also noted that the company had published results of a human study, which showed that a single…

FridayMar 01, 2024 12:09 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed the effectiveness of the company’s investigational new drug (“IND”) application thereby clearing Lexaria to conduct its planned U.S. Phase 1b hypertension clinical trial HYPER-H23-1 utilizing DehydraTECH-CBD. According to the announcement, the company is pleased to have complied with the FDA’s rules and procedures for clearance to perform this important registrational trial. The company will further announce when it is ready to begin the study, subject to certain conditions, including raising sufficient funding. “This is a significant…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX